Sonnet BioTherapeutics 宣布其股东已正式批准与 Hyperliquid ...

Group 1 - Sonnet BioTherapeutics has received formal approval from its shareholders for a business combination with Hyperliquid Strategies Inc and Rorschach I LLC [1] - The transaction has been submitted via Form S-4, and plans to have Hyperliquid Strategies listed on NASDAQ post-completion [1] - Hyperliquid Strategies has previously submitted an S-1 filing to raise up to $1 billion, which may be used for the acquisition of HYPE tokens [1]